<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04494061</url>
  </required_header>
  <id_info>
    <org_study_id>NI-0501-13</org_study_id>
    <nct_id>NCT04494061</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant</brief_title>
  <official_title>A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cytel Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioMérieux</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study designed to collect blood for research purposes in patients after&#xD;
      hematopoietic stem cell transplantation (HSCT) or in patients with a medical condition where&#xD;
      the blood cells production is impaired. The blood samples will be used to study the role of&#xD;
      Interferon gamma (IFNɣ) in graft failure or impairment of hematopoietic stem cell&#xD;
      proliferation. The IFNɣ signature will be assessed by measuring primarily IFNɣ and C-X-C&#xD;
      Motif Chemokine Ligand 9 (CXCL9).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study is designed to investigate IFNγ activity in two cohorts of patients.&#xD;
&#xD;
        -  First group will include patients post HSCT at risk of graft failure (GF) based on their&#xD;
           underlying diseases and on the transplant procedure.&#xD;
&#xD;
        -  Second group will contain patients with conditions where HSC proliferation is impaired&#xD;
           (e.g. aplastic anemia) and with matched controls (healthy volunteers (HV) samples&#xD;
           collected outside this clinical protocol).&#xD;
&#xD;
      IFNɣ activity will be assessed by measuring IFNγ and CXCL9 in serum.&#xD;
&#xD;
      For HSCT cohort, the following sampling time points are required: on day -7, pre HSCT on day&#xD;
      0, 1, 3, 5, 9, 13, 17, 21, 28, 31, 38 and one additional sample at the time when primary or&#xD;
      secondary GF is suspected if not on the planned schedule. In addition, the following time&#xD;
      points are recommended: day 7, 11, 15, 19, 24, 35, 42. It is also suggested to collect a&#xD;
      sample when Graft vs Host Disease (GVHD) is diagnosed during any visit that the patients will&#xD;
      attend as part of his/her standard treatment during the first 100 days post-transplant. The&#xD;
      patient will be followed up until around day 100 post-transplant. This follow up will consist&#xD;
      of capturing HSCT outcome information from patient hospital records around day 100.&#xD;
&#xD;
      For IHSCP cohort pre-transplant, it is recommended that, one sample per patient at the time&#xD;
      of diagnosis (if possible not more than 1 week from the date of diagnosis) is collected.&#xD;
      Age/sex matched control samples should be collected from healthy volunteers or patients with&#xD;
      malignant disease outside of this protocol after appropriate consent.&#xD;
&#xD;
      Different sets of data will be collected for the HSCT and IHSCP cohorts respectively as&#xD;
      described below:&#xD;
&#xD;
      Data collected for both cohorts&#xD;
&#xD;
        -  Age and sex&#xD;
&#xD;
        -  Inflammatory markers&#xD;
&#xD;
        -  IFNɣ&#xD;
&#xD;
        -  CXCL9&#xD;
&#xD;
        -  Other potential relevant exploratory biomarkers&#xD;
&#xD;
        -  Diagnosis&#xD;
&#xD;
        -  Date of disease diagnosis&#xD;
&#xD;
        -  Relevant medical history&#xD;
&#xD;
        -  Date and time of sample collection&#xD;
&#xD;
      Data collected for HSCT cohort only&#xD;
&#xD;
        -  Laboratory parameters assessed at the site laboratory on the date of sample collection&#xD;
           and between collection dates when available:&#xD;
&#xD;
        -  Absolute neutrophile count (ANC) and Platelets will be measured as per the schedule of&#xD;
           assessment, if possible when routine monitoring of patient health is conducted&#xD;
&#xD;
        -  Ferritin and Chimerism data will be collected when available (if measured as per site&#xD;
           routine practice)&#xD;
&#xD;
        -  Concomitant medications at the time of sample collection and between collection dates&#xD;
&#xD;
        -  Presence of infection at the time of sample collection with the date of onset&#xD;
&#xD;
        -  Presence of donor specific antibodies (DSA)&#xD;
&#xD;
        -  Transplant information&#xD;
&#xD;
        -  Date of start of conditioning&#xD;
&#xD;
        -  Type of conditioning (Reduced Intensity Conditioning (RIC) / Myeloablative Conditioning&#xD;
           (MAC) / Non-myeloablative Conditioning (NMAC) and medications&#xD;
&#xD;
        -  Transplant details (donor type, degree of match, transplant manipulation, stem cell&#xD;
           source)&#xD;
&#xD;
        -  Date of transplant&#xD;
&#xD;
        -  Date of primary / secondary GF or of confirmed engraftment&#xD;
&#xD;
        -  GVHD with the date of onset&#xD;
&#xD;
        -  Post-transplant treatment and date (Donor Lymphocyte Infusion (DLI), Stem Cell (SC)&#xD;
           boost, growth factor, GVHD prophylaxis, second HSCT procedure)&#xD;
&#xD;
      Data collected for IHSCP cohort only&#xD;
&#xD;
        -  Disease severity&#xD;
&#xD;
        -  In addition, the following data will be recorded for pediatric patients up to 18 years&#xD;
           old, if available:&#xD;
&#xD;
        -  PNH clones&#xD;
&#xD;
        -  History of hepatitis&#xD;
&#xD;
        -  Karyotype&#xD;
&#xD;
      Study duration:&#xD;
&#xD;
      The study will be conducted, until the required number of patients is recruited.&#xD;
&#xD;
        -  HSCT cohort: At patient level, the study will last about 100 days from pre-transplant&#xD;
           blood collection to last follow up data collection around day 100 post HSCT, matching&#xD;
           the standard HSCT patient care&#xD;
&#xD;
        -  IHSCP cohort: At patient level the study will last 1 day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HSCT cohort: IFNγ signature pre-and post-transplant</measure>
    <time_frame>Day (-7) to day 100</time_frame>
    <description>IFNγ, CXCL-9 and exploratory biomarkers in serum samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HSCT cohort: Relationship between IFNγ and the risk of graft failure</measure>
    <time_frame>Day (-7) to day 100</time_frame>
    <description>IFNγ and CXCL-9 in serum samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HSCT cohort: Relationship between IFNγ and the occurrence of GVHD</measure>
    <time_frame>Day (-7) to day 100</time_frame>
    <description>IFNγ and CXCL-9 in serum samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IHSCP cohort: IFNγ signature pre-transplant</measure>
    <time_frame>Day 1</time_frame>
    <description>IFNγ, CXCL-9 and exploratory biomarkers in serum samples</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Graft Failure</condition>
  <arm_group>
    <arm_group_label>HSCT - Hematopoetic Stem Cell Proliferation</arm_group_label>
    <description>Patients who received hematopoietic stem cell transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IHSCP - Impaired HSC proliferation</arm_group_label>
    <description>Patients with impaired hematopoietic stem cell proliferation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood collection</intervention_name>
    <description>Blood samples will be collected as per protocol defined schedule. There is no investigation drug in this study.</description>
    <arm_group_label>HSCT - Hematopoetic Stem Cell Proliferation</arm_group_label>
    <arm_group_label>IHSCP - Impaired HSC proliferation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Patients post HSCT at risk of graft failure based on their underlying diseases and on&#xD;
             the transplant procedure.&#xD;
&#xD;
          -  Patients with conditions where HSC proliferation is impaired (e.g. aplastic anemia)&#xD;
             and with respective controls (healthy volunteers (HV)).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have consented to the use of their clinical data and biological&#xD;
             samples for research investigations.&#xD;
&#xD;
          -  In HSCT cohort:&#xD;
&#xD;
               -  Patients with underlying:&#xD;
&#xD;
                  i. non-malignant hematological disease (e.g. autoimmune and metabolic disorders,&#xD;
                  aplastic anemia, Sickle cell anemia, Fanconi anemia, Diamond-blackfan anemia,&#xD;
                  thalassemia, osteopetrosis, Wiskott-Aldrich syndrome, severe combined&#xD;
                  immunodeficiency) or ii. malignant disease with higher risk of GF, i.e. Acute&#xD;
                  Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) with primary&#xD;
                  induction failure, second partial remission or relapse; Chronic Myeloid Leukemia&#xD;
                  (CML) in blastic phase (circulating blast or blast above 5% in biopsy); Non&#xD;
                  Hodgkin and Hodgkin Lymphoma and multiple myeloma with primary induction failure,&#xD;
                  second partial remission or relapse, myelodysplastic syndromes (MDS) and&#xD;
                  myeloproliferative disorders (MPD) with splenomegaly, myelofibrosis with portal&#xD;
                  hypertension pre-transplant, MDS/MPD overlap syndromes&#xD;
&#xD;
               -  and who received allogeneic HSCT and are at higher risk of graft failure based on&#xD;
                  at least one of the following criteria: i. Having received reduced intensity&#xD;
                  conditioning (RIC) or non myeloablative conditioning (NMA) combined with a&#xD;
                  non-malignant disease or having received graft from Bone Marrow (BM) ii. Ex vivo&#xD;
                  T cell depleted graft iii. Graft from mismatched unrelated donor or&#xD;
                  haploidentical donor iv. Graft from Umbilical Cord Blood (UCB)&#xD;
&#xD;
          -  In the IHSCP cohort:&#xD;
&#xD;
               -  Patients with IHSCP pre-transplant (e.g. aplastic anemia)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HLH patients&#xD;
&#xD;
          -  Body weight &lt; 10kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Regis Peffault de Latour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Louis Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuel Monnet, PhD</last_name>
    <phone>+41 22 593 82 33</phone>
    <email>Emmanuel.Monnet@sobi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Romana Dallamano</last_name>
    <phone>+41 79 82 16 275</phone>
    <email>romana.dallamano@sobi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Delta - Campus Rumbeke</name>
      <address>
        <city>Roeselare</city>
        <state>West-Vlaanderen</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dries Dereen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dries Dereen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier Poirier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xavier Poirier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Côte De Nacre</name>
      <address>
        <city>Caen cedex 9</city>
        <state>Basse-Normandie</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes cedex 9</city>
        <state>Bretagne</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional et Universitaire de Besançon - Hôpital Jean-Minjoz</name>
      <address>
        <city>Besançon Cedex</city>
        <state>Franche-Comte</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne Daguindau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Etienne Daguindau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Robert-Debré</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpitaux de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <state>Lorraine</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hosptitalier Universitaire d'Angers</name>
      <address>
        <city>Angers Cedex 9</city>
        <state>Maine Et Loire</state>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <state>Nouvelle Aquitaine</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <state>Provence Alpes Cote d'Azur</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <state>Provence Alpes Cote d'Azur</state>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Grenoble Alpes</name>
      <address>
        <city>La Tronche</city>
        <state>Rhone-Alpes</state>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude-Eric Bulabois, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claude-Eric Bulabois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Rhône</state>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Lang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Lang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù - Roma - Gianicolo</name>
      <address>
        <city>Roma</city>
        <state>Lombardia</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pietro Merli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pietro Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Risitano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maura Faraci, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maura Faraci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio Ciceri, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fabio Ciceri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Zecca, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marco Zecca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Regina Margherita</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franca Facioli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Franca Facioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prinses Maxima Centrum Kinderoncologie</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Lindemans, MD</last_name>
    </contact>
    <investigator>
      <last_name>Caroline LIndemans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiff and Vale University Health Board</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wendy Ingram, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wendy Ingram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital - London</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emma Nicholson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emma Nicholson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renuka Palanicawandar, MD</last_name>
    </contact>
    <investigator>
      <last_name>Renuka Palanicawandar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2020</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

